Dramatic advances in disease-modifying treatment options for patients with generalized myasthenia gravis (gMG) have emerged in the past several years; these have targeted FcRn receptors and various specific targets within the complement cascade. Clinicians who manage or co-manage patients with gMG should now be made aware of a novel and different approach with an investigational, first-in-class recombinant dual transmembrane activator and calcium modulator and cyclophilin ligand interactor fusion protein (TACI Fc) that is designed to inhibit the development and survival of plasma cells and mature B-cells. This approach would potentially prevent the formation of autoantibodies in patients with gMG by targeting and neutralizing two cytokines, B-cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). New Phase 3 data on this emerging treatment approach were presented in late October 2025 at the AANEM Annual Meeting in San Francisco. Our expert neuromuscular faculty review those data and their potential contextualization into gMG treatment regimens after explaining this novel mechanism of action. As our Program Chair, Dr. James Howard, has often stated, ’There has never been a more exciting time in gMG therapeutics’. Join us for this continuing education program to stay up to date on the latest advances.